Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database

John Pfail(Icahn School of Medicine at Mount Sinai), John P. Sfakianos(Mount Sinai Medical Center), Kyrollis Attalla(Memorial Sloan Kettering Cancer Center), Ishan Paranjpe(Icahn School of Medicine at Mount Sinai), Reza Mehrazin(Icahn School of Medicine at Mount Sinai), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), François Audenet(Université Paris Cité), Alberto Martini(The University of Texas MD Anderson Cancer Center), Nir Tomer(Icahn School of Medicine at Mount Sinai), Nikhil Waingankar(Icahn School of Medicine at Mount Sinai), Jorge Daza(Icahn School of Medicine at Mount Sinai), Peter Wiklund(Unknown)
Bladder Cancer
June 12, 2020
10.3233/blc-200303
Cited by 17

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786